About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Advancements in Previously Untreated Patients with DLBCL
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
U
Current Standards of Care for Aggressive Lymphomas
By
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
FEATURING
Umberto Vitolo
By
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
FEATURING
Umberto Vitolo
213 views
February 21, 2024
0 Comments
Login to view comments.
Click here to Login
22:11
SOHO Brazil 2024
Has the 1L SoC Truly Changed in Advanced Stage DLBCL?
Feat.
A. Zelenetz
20:25
SOHO Brazil 2024
What Is the Best Timing for Bispecific Antibodies and CAR-T Therapy …
Feat.
A. Zelenetz
15:02
SOHO Brazil 2024
Summary of Updates in R/R DLBCL Treatment
Feat.
A. Alencar
37:44
University of Colorado Division of Hematology
Summary and Practice Impacts of Recent Updates in B-Cell Lymphomas
Feat.
M. Kamdar
15:26
Moffitt Cancer Center
R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?
Feat.
A. Lazaryan
04:29
Juan Pablo Alderuccio
Polatuzumab Vedotin in 1L DLBCL: Perspectives on the POLARIX Trial
31:12
UChicago Medicine
Practice-Changing Abstracts in NHL and HL From ASH 2023
Feat.
S. Smith
04:37
Thomas Melchardt
POLARIX Trial Recap: Using Polatuzumab Vedotin for Previously Untrea…
08:01
Georg Lenz
Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC
35:24
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: Aggressive B-Cell Lymphomas
Feat.
G. Nowakowski
29:26
Massachusetts General Hospital Cancer Center
Practice-Changing Updates in DLBCL and HL
Feat.
J. Erika Haydu
22:09
Scripps Health
New Updates in Frontline DLBCL
Feat.
L. Nastoupil
09:32
SOHO 2023 Eleventh Annual Meeting
Upfront Management of DLBCL
Feat.
C. Flowers
35:27
Louisville Hematology Highlights
Updates on Management of DLBCL
Feat.
J. Leonard
27:47
Indy Hematology Review
Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…
Feat.
S. Smith
04:04
Wojciech Jurczak
Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial